[go: up one dir, main page]

DE69434469T2 - Zusammensetzungen und verfahren zur verabreichung von genetischem material - Google Patents

Zusammensetzungen und verfahren zur verabreichung von genetischem material Download PDF

Info

Publication number
DE69434469T2
DE69434469T2 DE69434469T DE69434469T DE69434469T2 DE 69434469 T2 DE69434469 T2 DE 69434469T2 DE 69434469 T DE69434469 T DE 69434469T DE 69434469 T DE69434469 T DE 69434469T DE 69434469 T2 DE69434469 T2 DE 69434469T2
Authority
DE
Germany
Prior art keywords
individual
methods
protein
disclosed
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434469T
Other languages
English (en)
Other versions
DE69434469D1 (de
Inventor
Davi B Weiner
William V Williams
Bin Wang
Leslie R Coney
Michael J Merva
Vincent R Zurawski Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
University of Pennsylvania Penn
Wistar Institute of Anatomy and Biology
Original Assignee
Wyeth LLC
University of Pennsylvania Penn
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/125,012 external-priority patent/US5593972A/en
Application filed by Wyeth LLC, University of Pennsylvania Penn, Wistar Institute of Anatomy and Biology filed Critical Wyeth LLC
Priority claimed from US08/979,385 external-priority patent/US5981505A/en
Priority claimed from US09/359,975 external-priority patent/US7001759B1/en
Publication of DE69434469D1 publication Critical patent/DE69434469D1/de
Application granted granted Critical
Publication of DE69434469T2 publication Critical patent/DE69434469T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE69434469T 1993-01-26 1994-01-26 Zusammensetzungen und verfahren zur verabreichung von genetischem material Expired - Lifetime DE69434469T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US834293A 1993-01-26 1993-01-26
US2933693A 1993-03-11 1993-03-11
US9323593A 1993-07-15 1993-07-15
US12496293A 1993-09-21 1993-09-21
US08/125,012 US5593972A (en) 1993-01-26 1993-09-21 Genetic immunization
PCT/US1994/000899 WO1994016737A1 (en) 1993-01-26 1994-01-26 Compositions and methods for delivery of genetic material
US08/979,385 US5981505A (en) 1993-01-26 1994-01-26 Compositions and methods for delivery of genetic material
US49568495A 1995-08-28 1995-08-28
US09/359,975 US7001759B1 (en) 1993-01-26 1999-07-23 Compositions and methods for delivery of genetic material

Publications (2)

Publication Number Publication Date
DE69434469D1 DE69434469D1 (de) 2005-09-29
DE69434469T2 true DE69434469T2 (de) 2006-06-14

Family

ID=38247352

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69434469T Expired - Lifetime DE69434469T2 (de) 1993-01-26 1994-01-26 Zusammensetzungen und verfahren zur verabreichung von genetischem material

Country Status (14)

Country Link
US (1) US8304234B2 (de)
EP (1) EP0681483B1 (de)
JP (1) JP3701966B2 (de)
AT (1) ATE302854T1 (de)
AU (1) AU675702B2 (de)
CA (1) CA2153593C (de)
DE (1) DE69434469T2 (de)
DK (1) DK0681483T3 (de)
ES (1) ES2249760T3 (de)
HU (1) HU219767B (de)
IL (1) IL108449A (de)
NZ (1) NZ262582A (de)
PT (1) PT681483E (de)
WO (1) WO1994016737A1 (de)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2169635C (en) * 1993-08-26 2002-11-12 Dennis A. Carson Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides
US6348449B1 (en) 1993-09-21 2002-02-19 The Trustees Of The University Of Pennsylvania Methods of inducing mucosal immunity
US6235888B1 (en) 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
RU2189254C2 (ru) * 1995-06-06 2002-09-20 Америкэн Хоум Продактс Корпорэйшн Вакцины против вирусов гепатита
USRE38490E1 (en) 1995-11-16 2004-04-06 Baylor College Of Medicine Method for identifying metastatic sequences
WO1997025860A1 (en) * 1996-01-19 1997-07-24 Allegheny University Of The Health Sciences Cellular immunogens useful as cancer vaccines
USRE38392E1 (en) 1996-01-30 2004-01-20 Baylor College Of Medicine Method for identifying metastatic sequences
US6168918B1 (en) 1996-01-31 2001-01-02 American Home Products Corp. Method of detecting foreign DNA integrated in eukaryotic chromosomes
US6534312B1 (en) 1996-02-22 2003-03-18 Merck & Co., Inc. Vaccines comprising synthetic genes
HUP9901112A3 (en) * 1996-02-22 2001-06-28 Merck & Co Inc Synthetic hiv genes
US5851804A (en) * 1996-05-06 1998-12-22 Apollon, Inc. Chimeric kanamycin resistance gene
US7235056B2 (en) 1996-05-17 2007-06-26 Amira Medical Body fluid sampling device and methods of use
US20020010406A1 (en) 1996-05-17 2002-01-24 Douglas Joel S. Methods and apparatus for expressing body fluid from an incision
US7828749B2 (en) 1996-05-17 2010-11-09 Roche Diagnostics Operations, Inc. Blood and interstitial fluid sampling device
US7666150B2 (en) 1996-05-17 2010-02-23 Roche Diagnostics Operations, Inc. Blood and interstitial fluid sampling device
EP1579814A3 (de) 1996-05-17 2006-06-14 Roche Diagnostics Operations, Inc. Verfahren und Vorrichtung zur Probenahme und Analyse von Körperflüssigkeit
US5846946A (en) * 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
WO1997048370A2 (en) * 1996-06-21 1997-12-24 Merck & Co., Inc. Vaccines comprising synthetic genes
EP0934083B1 (de) * 1996-10-23 2009-04-29 The Trustees Of The University Of Pennsylvania Verbesserte impfstoffe
AU734443C (en) * 1996-10-23 2005-04-14 Wyeth Vaccines
EP0941356A2 (de) * 1996-11-01 1999-09-15 Genespan Corporation Stabilisierte transiente genexpression
US6146847A (en) * 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
WO1998024912A2 (en) * 1996-12-04 1998-06-11 Heska Corporation Recombinant plague vaccine
GB9626539D0 (en) * 1996-12-20 1997-02-05 Univ Liverpool A method of enhancing the rate of transfection of cells
CN1252075A (zh) * 1997-02-07 2000-05-03 麦克公司 合成的hiv gag基因
US6696291B2 (en) 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
US6217900B1 (en) * 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
AU8298298A (en) * 1997-07-08 1999-02-08 Chiron Corporation Use of submicron oil-in-water emulsions with dna vaccines
EP0893507A1 (de) * 1997-07-25 1999-01-27 Institut Gustave Roussy Verwendung von MHC Klass II Liganden (CD4 und LAG-3) als Adjuvanz für Impfungen und von LAG-3 in der Behandlung von Krebs
US6818627B1 (en) 1997-08-14 2004-11-16 The Trustees Of The University Of Pennsylvania Functional fragments of HIV-1 Vpr protein and methods of using the same
DK2044950T3 (da) 1997-09-18 2012-09-17 Univ Pennsylvania Svækkede VIF-DNA-immuniseringskassetter til genetiske vacciner
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
CA2306733A1 (en) 1997-10-28 1999-05-06 American Home Products Corporation Compositions and methods for delivery of genetic material
US6252058B1 (en) 1997-11-05 2001-06-26 Timothy C. Thompson Sequences for targeting metastatic cells
CN101126094A (zh) * 1998-01-30 2008-02-20 总医院有限公司 采用丙型肝炎病毒非结构蛋白进行的基因免疫
CA2323074A1 (en) 1998-03-13 1999-09-16 Baylor College Of Medicine Compositions and methods for the treatment and prevention of metastatic disorders
WO2000011181A1 (en) 1998-08-20 2000-03-02 Connaught Laboratories Limited NUCLEIC ACID MOLECULES ENCODING INCLUSION MEMBRANE PROTEIN C OF $i(CHLAMYDIA)
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
FR2785293B1 (fr) 1998-10-30 2002-07-05 Pasteur Merieux Serums Vacc Acides nucleiques et polypeptides specifiques des souches pathogenes du genre neisseria
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US6602705B1 (en) 1998-12-31 2003-08-05 Chiron Corporation Expression of HIV polypeptides and production of virus-like particles
EP2363478B1 (de) 1999-04-21 2019-07-24 Alnylam Pharmaceuticals, Inc. Verfahren und Zusammensetzungen zur Hemmung der Funktion der Polynukleotide Sequenzen
CN1196495C (zh) 1999-04-30 2005-04-13 宾夕法尼亚大学理事会 突变的人cd80及其制备和应用组合物和方法
WO2001030847A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
BR0016593A (pt) 1999-12-22 2002-12-03 Univ Pennsylvania Métodos para induzir uma resposta imune em um indivìduo contra um patógeno, para tratar um indivìduo suscetìvel a ou que sofre de uma doença associada com um defeito genético e para liberar uma proteìna a um indivìduo, e, composição farmacêutica
WO2001059071A2 (en) 2000-02-09 2001-08-16 Genvec, Inc. Methods of preparing and using a viral vector library
ATE404698T1 (de) 2000-04-18 2008-08-15 Virco Bvba Methode zur bestimmung der resistenz gegen medikamente
EP1792995A3 (de) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia Antigene, entsprechende DNS Fragmente und ihre Verwendungen
PT1282702E (pt) 2000-05-10 2007-02-28 Ludwig Inst Cancer Res Polipéptidos imunogénicos codificados por minigenes mage e suas utilizações
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
RU2286172C2 (ru) 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
DE60130998T2 (de) 2000-08-17 2008-07-17 Tripep Ab Ribavirin-enthaltende vakzine
WO2002016440A2 (en) 2000-08-25 2002-02-28 Aventis Pasteur Limited Haemophilus influenzae lipopolysaccharide inner-core oligosaccharide epitopes as vaccines for the prevention of haemophilus influenzae infections
CZ20031992A3 (cs) 2001-01-22 2004-11-10 F. Hoffmann-La Roche Ag Lancetové zařízení s kapilární vzlínavostí
US8216585B2 (en) 2001-05-25 2012-07-10 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
EP1285971B1 (de) * 2001-08-08 2007-10-10 Tibotec Pharmaceuticals Ltd. Verfahren zur phänotypischen und genotypischen Bestimmung der Arzneimittelsensitivität von HIV Intergase-Varianten
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
DE10142232B4 (de) 2001-08-29 2021-04-29 Roche Diabetes Care Gmbh Verfahren zur Herstellung eines analytischen Hilfsmittels mit Lanzette und Testelement
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7462491B2 (en) 2002-01-31 2008-12-09 Baylor College Of Medicine Methods and compositions for diagnosis and monitoring of prostate cancer progression by detection of serum caveolin
IL163988A0 (en) 2002-03-15 2005-12-18 Wyeth Corp Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
EP1356820A1 (de) 2002-04-26 2003-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) DNA-Impfstoff kombiniert mit einen Apoptoneauslöser von Tumorzellen
US20040180438A1 (en) 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
AU2003243663A1 (en) 2002-06-20 2004-01-06 The Trustees Of The University Of Pennsylvania Vaccines for suppressing ige-mediated allergic disease and methods for using the same
MXPA05004588A (es) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
CN100379853C (zh) 2002-11-19 2008-04-09 宾夕法尼亚州大学信托人 包含rre和cte的遗传构建体和组合物及其用途
NZ570709A (en) 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
ATE535249T1 (de) 2003-06-13 2011-12-15 Univ Pennsylvania Vakzine, immuntherapeutika und verfahren zu ihrer verwendung
ES2616337T3 (es) 2003-12-12 2017-06-12 Government Of The United States Of America, As Repr. By The Secr. Of The Dept. Of Health And Human Services And His Successors Un epítopo de linfocito T citotóxico humano y su epítopo agonista del número no variable de secuencias de repetición en tándem de MUC-1
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
EP2213298A3 (de) * 2004-10-21 2011-07-20 Wyeth LLC Imunogene Zusammensetzungen von Staphylococcus Epidermidis Polypeptide und Polynucleotide Antigenen
US20080274140A1 (en) 2004-11-19 2008-11-06 David B Weiner Vaccines and Methods for Using the Same
JP5346588B2 (ja) 2006-01-13 2013-11-20 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア コドン最適化したｉｌ−１５を用いるワクチンおよび免疫治療とその使用方法
WO2007082105A2 (en) 2006-01-16 2007-07-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chlamydia vaccine
US8921050B2 (en) 2006-03-17 2014-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of diagnosing renal cell carcinoma
CA3057039C (en) 2006-07-28 2023-02-28 The Trustees Of The University Of Pennsylvania Hiv consensus envelope sequences and methods for using same
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
WO2009073330A2 (en) 2007-11-12 2009-06-11 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of influenza virus
JP2011504173A (ja) 2007-11-14 2011-02-03 ブイジーエックス ファーマシューティカルズ，リミティド ライアビリティー カンパニー 電気穿孔により送達されるｄｎａワクチンにより誘導される抗体の産生
KR101708277B1 (ko) 2008-05-28 2017-02-20 이노비오 파마수티컬즈, 인크. 천연두 ｄｎａ 백신 및 면역 반응을 유도하는 상기 백신 내에 항원
KR101609233B1 (ko) 2008-10-29 2016-04-05 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개량된 ｈｃｖ 백신 및 이를 이용하는 방법
US8921536B2 (en) 2008-10-29 2014-12-30 The Trustees Of The University Of Pennsylvania HCV vaccines and methods for using the same
CA3001374A1 (en) 2008-11-17 2010-05-20 Vgx Pharmaceuticals, Llc Antigens that elicit immune response against flavivirus and methods of using same
US9050287B2 (en) 2009-01-23 2015-06-09 The Trustees Of The University Of Pennsylvania Vaccines for human papilloma virus and methods for using the same
CA2653478A1 (en) 2009-01-23 2010-07-23 Gregg Martin Automated wash system for industrial vehicles
CN102439150A (zh) 2009-03-27 2012-05-02 法国国家健康医学研究院 用于癌症治疗的卡那霉素反义核酸
KR102138780B1 (ko) 2009-11-02 2020-07-29 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 구제역 바이러스(ｆｍｄｖ) 공통 단백질, 이를 위한 코딩 서열 및 이로부터 만들어진 백신
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
KR101784177B1 (ko) 2010-02-08 2017-10-11 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｒａｎｔｅｓ를 암호화하는 핵산 분자, 그리고 이를 포함하는 조성물 및 이의 사용 방법
KR20180096814A (ko) 2010-09-27 2018-08-29 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 공통 항원 구성체 및 이것으로부터 만들어진 백신 및 말라리아를 치료하기 위한 이것의 사용방법
SI3536703T1 (sl) 2010-11-12 2022-04-29 The Trustees Of The University Of Pennsylvania Konsenzni prostatični antigeni, molekule nukleinske kisline, ki jih kodirajo in uporabe le-teh
AU2012212264B2 (en) 2011-01-31 2016-01-28 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
HUE049669T2 (hu) 2011-02-11 2020-10-28 Univ Pennsylvania Hepatitis B vírus magfehérjéjét kódoló nukleinsav-molekula és azt tartalmazó oltóanyag
EP2717922B1 (de) 2011-06-10 2018-09-12 Bluebird Bio, Inc. Gentherapievektoren für adrenoleukodystrophie und adrenomyeloneuropathie
JP6117781B2 (ja) 2011-07-11 2017-04-19 イノビオ ファーマシューティカルズ，インコーポレイティド 交差防御性アレナウイルスワクチンおよびそれらの使用方法
WO2013090296A1 (en) 2011-12-12 2013-06-20 The Trustees Of The University Of Pennsylvania Compositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same
US9750795B2 (en) 2011-12-12 2017-09-05 The Trustees Of The University Of Pennsylvania Proteins comprising MRSA PBP2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat MRSA infections
CA2870182A1 (en) 2012-04-10 2013-10-17 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
US9597388B2 (en) 2012-04-12 2017-03-21 The Trustees Of The University Of Pennslyvania Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
US9738879B2 (en) 2012-04-27 2017-08-22 Duke University Genetic correction of mutated genes
EP3597741A1 (de) 2012-04-27 2020-01-22 Duke University Genetische korrektur mutierter gene
MX364732B (es) 2012-12-13 2019-05-06 Univ Pennsylvania Vacuna contra el tumor de wilms 1.
JP6517779B2 (ja) 2013-03-12 2019-05-22 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスの改良型ワクチンおよびその使用方法
US9993545B2 (en) 2013-03-15 2018-06-12 The Trustees Of The University Of Pennsylvania Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom
MX369709B (es) 2013-03-15 2019-11-19 Univ Pennsylvania Vacunación mejorada contra tirosinasa.
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
EP3539573B1 (de) 2013-06-05 2024-02-14 Duke University Rna-geführte genmanipulation und genregulierung
EP4176897A1 (de) 2013-06-25 2023-05-10 International AIDS Vaccine Initiative, Inc. Tuberkulosezusammensetzungen und verfahren zur verwendung davon
CN105829341A (zh) 2013-12-13 2016-08-03 宾夕法尼亚大学理事会 Dna抗体构建体及其使用方法
EP3169699A4 (de) 2014-07-18 2018-06-20 The University of Washington Krebsimpfstoffzusammensetzungen und verfahren zur verwendung davon
US11319555B2 (en) 2014-11-20 2022-05-03 Duke University Compositions, systems and methods for cell therapy
CN114010802A (zh) 2014-12-01 2022-02-08 宾夕法尼亚大学理事会 Dna抗体构建体及其使用方法
EP3256487A4 (de) 2015-02-09 2018-07-18 Duke University Zusammensetzungen und verfahren zur epigenombearbeitung
WO2016179034A2 (en) 2015-05-01 2016-11-10 The Trustees Of The University Of Pennsylvania Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs
ES3009026T3 (en) 2015-07-22 2025-03-25 Duke Univ High-throughput screening of regulatory element function with epigenome editing technologies
EP4345455A3 (de) 2015-08-25 2024-07-17 Duke University Zusammensetzungen und verfahren zur verbesserung der spezifität in der genomischen manipulation unter verwendung von rna-geführten endonukleasen
EP3362571A4 (de) 2015-10-13 2019-07-10 Duke University Genom-engineering mit typ-i-crispr-systemen in eukaryotischen zellen
US11180538B2 (en) 2015-11-13 2021-11-23 University Of Utah Research Foundation Combinatorial gene construct and non-viral delivery for anti-obesity
CN108779466B (zh) 2015-11-30 2024-03-29 杜克大学 用于通过基因编辑修正人肌营养不良蛋白基因的治疗靶标和使用方法
MX2018009506A (es) 2016-02-05 2019-05-06 Inovio Pharmaceuticals Inc Vacunas contra el cáncer y métodos de tratamiento que las utilizan.
US20190134221A1 (en) 2016-05-05 2019-05-09 Duke University Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy
EP3471763A4 (de) 2016-06-16 2020-04-29 International AIDS Vaccine Initiative, Inc. Tuberkulosezusammensetzungen und verfahren zur behandlung oder vorbeugung von tuberkulose
WO2017223146A1 (en) 2016-06-22 2017-12-28 Aeras Recombinant cytomegalovirus vectors as vaccines for tuberculosis
EP4275747A3 (de) 2016-07-19 2024-01-24 Duke University Therapeutische anwendungen von cpf1-basierter genomeditierung
WO2018081504A1 (en) 2016-10-28 2018-05-03 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus
WO2019079155A1 (en) 2017-10-17 2019-04-25 International Aids Vaccine Initiative, Inc. CASSETTES OF ANTIGENS OF TUBERCULOSIS
US11154601B2 (en) 2017-12-13 2021-10-26 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting BORIS and uses thereof
PL3737397T3 (pl) 2017-12-13 2023-03-27 Inovio Pharmaceuticals, Inc. Szczepionki przeciwnowotworowe ukierunkowane do prame i ich zastosowania
MX2020006217A (es) 2017-12-13 2020-12-03 Inovio Pharmaceuticals Inc Vacunas de cáncer dirigidas a muc16 y sus usos.
CA3083528C (en) 2017-12-13 2023-09-12 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting mesothelin and uses thereof
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi
KR20220113442A (ko) 2019-12-06 2022-08-12 스크라이브 테라퓨틱스 인크. 입자 전달 시스템
EP4351660A2 (de) 2021-06-09 2024-04-17 Scribe Therapeutics Inc. Partikelabgabesysteme
WO2023227669A2 (en) 2022-05-26 2023-11-30 UCB Biopharma SRL Novel nucleic acid-editing proteins
IL317874A (en) 2022-06-24 2025-02-01 Tune Therapeutics Inc Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression
WO2024200831A1 (en) 2023-03-30 2024-10-03 Vivadju Pvax14 nucleic acid in combination with all-trans retinoic acid (atra) and a checkpoint inhibitor for the treatment of cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3688765A (en) * 1969-10-03 1972-09-05 Jack S Gasaway Hypodermic injection device
GB1594097A (en) * 1976-12-16 1981-07-30 Int Inst Of Differentiation Production of specific immune nucleic acids cell dialysates and antibodies
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) * 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
GB8508845D0 (en) * 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4680027A (en) * 1985-12-12 1987-07-14 Injet Medical Products, Inc. Needleless hypodermic injection device
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5024656A (en) * 1988-08-30 1991-06-18 Injet Medical Products, Inc. Gas-pressure-regulated needleless injection system
US5185254A (en) * 1988-12-29 1993-02-09 The Wistar Institute Gene family of tumor-associated antigens
JP3140757B2 (ja) 1989-02-06 2001-03-05 デイナ・フアーバー・キヤンサー・インステイテユート パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用
CA2357538A1 (en) * 1989-03-21 1990-10-04 Wisconsin Alumni Research Foundation Expression of exogenous polynucleotide sequences in a vertebrate
US6214804B1 (en) * 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
JPH05503629A (ja) 1989-11-20 1993-06-17 オンコーゲン　リミテッド　パートナーシップ 抗ウィルス剤及び免疫原として使用される、非複製組換え製レトロウィルス粒子
CA2071214C (en) * 1989-12-21 2006-06-06 Alan Frankel Method of delivering molecules into eukaryotic cells
WO1991012329A2 (en) * 1990-02-12 1991-08-22 Board Of Regents, The University Of Texas System Satellite cell proliferation in adult skeletal muscle
EP0584279B1 (de) * 1991-05-14 2001-03-14 The University Of Connecticut Gerichtete abgabe von genen, die immunogene proteine kodieren
PT584348E (pt) * 1992-03-11 2005-10-31 Powderject Vaccines Inc Vacina genetica para virus da imunodeficiencia
WO1993023552A1 (en) 1992-05-21 1993-11-25 Government Of The United States As Represented By Secretary Department Of Health And Human Services Targeting gene expression to living tissue using jet injection
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization

Also Published As

Publication number Publication date
PT681483E (pt) 2005-11-30
CA2153593C (en) 2010-04-13
CA2153593A1 (en) 1994-08-04
NZ262582A (en) 1997-10-24
AU675702B2 (en) 1997-02-13
WO1994016737A1 (en) 1994-08-04
DE69434469D1 (de) 2005-09-29
EP0681483B1 (de) 2005-08-24
HUT73099A (en) 1996-06-28
EP0681483A4 (de) 1997-06-25
DK0681483T3 (da) 2005-11-21
ATE302854T1 (de) 2005-09-15
HU219767B (hu) 2001-07-30
EP0681483A1 (de) 1995-11-15
ES2249760T3 (es) 2006-04-01
JPH08509694A (ja) 1996-10-15
JP3701966B2 (ja) 2005-10-05
IL108449A (en) 2011-09-27
HU9502229D0 (en) 1995-09-28
US8304234B2 (en) 2012-11-06
IL108449A0 (en) 1994-04-12
AU6232094A (en) 1994-08-15
US20060222629A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
DE69434469T2 (de) Zusammensetzungen und verfahren zur verabreichung von genetischem material
DE69535035D1 (de) Präparate zur verabreichung von genetischem material
AR003423A1 (es) Anticuerpos monoclonales humanos de alta afinidad especificos de la proteina- f del rsv, celulas eucarioticas transfectadas; secuencia de adn y vector de expresion que lo codifican; metodo que utiliza los anticuerpos; una composicion farmaceutica que los contiene; metodo para detectar rsv y un kit de ensayo.
Milstein Chemical structure of light chains
ATE352638T1 (de) REVERSE ßTWO-HYBRIDß-SYSTEME
DE69840387D1 (de) Nik proteine, nukleinsäure sowie verfahren
AR018603A1 (es) Un peptido, util para el tratamiento y/o profilaxis de la enfermedad de alzheimer y el sindrome de down, las composiciones farmaceuticas y vacunas que locontienen, el uso de dicho peptido para la preparacion de las composiciones farmaceuticas, una secuencia de aislado de adn, un plasmido o vector vi
PT642581E (pt) Vacinas de clostridium perfringens
ATE133681T1 (de) Mykobakterielle rekombinanten und peptide
ATE270303T1 (de) Gc1q-rezeptor, daran bindende hiv-1 gp120-region, verwandte peptide und antikörper
DE69831007D1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
Chin et al. Selective associations of hormonal steroids with aminoacyl transfer RNAs and control of protein synthesis
WO1996018646A3 (en) Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
KR920012440A (ko) 인간 인터류킨-5 수용체
ATE266731T1 (de) Neue menschliche proteine, die cyclin abhängigen kinasen ähneln, sowie methoden zu deren verwendung
ATE420193T1 (de) Zusammensetzung zur verabreichung genetischen materials
Marx How peptide hormones get ready for work: researchers seem to have found the enzymes that clip peptide hormones and neurotransmitters out of their precursors
Jack et al. Immunoaffinity chromatography of clinical products
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
EP1570051A4 (de) Rre und cte umfassende gentechnische konstrukte und zusammensetzungen und verwendungen davon
RU2221873C2 (ru) Способ получения каталитических антител (варианты), антигены для иммунизации и нуклеотидная последовательность
KR960700077A (ko) 유전자 물질 전달용 조성물 및 전달 방법(Compositions and Methods for Delivery of Genetic Material)
KR830002027A (ko) 재결합 dna 분자의 제조 방법

Legal Events

Date Code Title Description
8364 No opposition during term of opposition